Seven Deaths in September
On the morning of September 29, 1982, a twelve-year-old girl named Mary Kellerman stayed home from school with a runny nose and a headache. Her parents told her to take a couple of Tylenol and rest. Her father heard her walk into the bathroom, heard the door close, heard something drop. He called her name twice. No answer. When he opened the door, Mary was on the floor in her pajamas, unconscious. She was pronounced dead at a Chicago-area hospital from what no one could yet explain.
A few hours later, twenty-seven-year-old postal worker Adam Janus took two Extra-Strength Tylenol for a headache at his home in a nearby suburb. He collapsed almost instantly. His younger brother and sister-in-law, grief-stricken at his wake, reached for the same bottle. They were the next to die. By the end of September 30, seven people in the Chicago metropolitan area had been killed by cyanide-laced capsules placed inside Tylenol bottles on pharmacy shelves — a mother of four with a week-old infant, a flight attendant found days later with an open bottle still on her bathroom counter. The murderer was never caught.
What happened next became the most studied crisis response in the history of American business. Johnson & Johnson — then a $5.4 billion conglomerate already ninety-six years old, its name synonymous with the soft, powdery innocence of the nursery — pulled thirty-one million bottles of Tylenol from store shelves at a cost exceeding $100 million. It introduced tamper-proof packaging that would become an industry standard, then a federal requirement. CEO James Burke went on 60 Minutes and The Donahue Show, projecting transparency at a moment when corporate instinct overwhelmingly favored silence. Tylenol's market share, which had collapsed from 37% to 7% overnight, clawed back to 30% within a year. The product survived. The brand survived. The company's reputation didn't just survive — it was transformed into something approaching secular sainthood.
For four decades, the Tylenol crisis has been taught at every business school as the canonical case study in values-driven leadership. And for four decades, Johnson & Johnson has traded on that reputation — the company that put consumers first, that lived its Credo, that chose principle over profit when the world was watching.
The question that defines Johnson & Johnson in the twenty-first century is whether the Tylenol crisis revealed the company's character or merely established a mythology powerful enough to survive the accumulation of contrary evidence.
By the Numbers
Johnson & Johnson at a Glance (FY 2024)
$88.8BTotal revenue (fiscal year 2024)
~$380BMarket capitalization (mid-2025)
~94,000Employees worldwide (post-Kenvue)
$55.4BInnovative Medicine segment revenue
$33.4BMedTech segment revenue
62Consecutive years of dividend increases
8Total CEOs in 139-year history
$9B+Proposed talc settlement (rejected by courts, 2025)
Three Brothers and a Bandage
The founding mythology is simpler than most. In January 1886 — the same year Coca-Cola was mixed in an Atlanta pharmacy and Karl Benz patented the automobile — three brothers named Johnson incorporated a company in New Brunswick, New Jersey, to manufacture sterile surgical dressings. Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson were not scientists or physicians. They were businessmen who had attended a lecture by the British antiseptic surgery pioneer Joseph Lister and recognized that his ideas about germs and sterile procedure, still controversial in American medicine, represented an enormous commercial opportunity. The gap between what science knew and what surgical practice did was, quite literally, killing people. The Johnsons proposed to fill it with a product.
Their first factory, a former wallpaper plant on the banks of the Raritan River, began producing gauze bandages and surgical dressings wrapped in individual packages — a radical concept when most hospitals still made their own from bulk cotton that was neither sterile nor standardized. The company grew quickly through a combination of genuine innovation (the development of mass-produced sterile sutures, the publication of a widely distributed guide called Modern Methods of Antiseptic Wound Treatment) and relentless commercial hustle. Edward Mead Johnson left in 1897 to found what became Mead Johnson & Company. Robert Wood Johnson I, the eldest and the driving force, died in 1910. But the entity he created survived the transition because the family's second generation proved even more consequential than the first.
Robert Wood Johnson II — known within the company as "the General" for his World War II service — took the company public in 1944 and, more importantly, authored the document that would become Johnson & Johnson's most durable competitive asset: the Credo.
Robert Wood Johnson II's 1943 stakeholder framework
Written a year before J&J's IPO, the Credo was a single-page statement of corporate responsibility that listed the company's obligations in a specific, deliberate order: first to doctors, nurses, patients, and mothers who use its products; second to its employees; third to the communities in which it operates; and last — explicitly, pointedly last — to its stockholders. "When we operate according to these principles," Johnson wrote, "the stockholders should realize a fair return."
This was radical for 1943. It remains radical now. The Credo's hierarchy inverted the prevailing logic of shareholder primacy decades before anyone called it "stakeholder capitalism." It gave the company a rhetorical framework — and, its defenders argue, an operational discipline — that other firms spent the next eighty years trying to copy without ever quite reproducing the original.
The General ran J&J for nearly three decades, transforming it from a surgical supply company into a diversified healthcare conglomerate. He pioneered what would become the company's defining structural innovation: extreme decentralization. Rather than consolidating acquired businesses into a single operating unit, Johnson let each subsidiary operate with extraordinary autonomy — its own president, its own P&L, its own culture, its own relationship with its market. The parent company provided capital, strategic guidance, and the Credo. Everything else was local.
This was not philosophical whimsy. The General believed that healthcare markets were too diverse, too local, and too technically specialized for centralized management to serve them well. A surgeon in São Paulo had different needs than a pediatrician in New Jersey, and both had different needs than a consumer mother buying baby shampoo. The decentralized model allowed J&J to compete simultaneously in pharmaceuticals, medical devices, and consumer health — three industries with fundamentally different innovation cycles, regulatory regimes, and distribution channels — without forcing any of them into a single operating template.
By the time the General died in 1968, Johnson & Johnson operated over a hundred subsidiary companies across dozens of countries. The architecture he built would outlast him by more than half a century, surviving multiple CEO transitions, industry upheavals, and — eventually — a series of crises that tested whether the Credo was a living document or a decorative plaque.
The Credo as Operating System
What made the Credo more than corporate wallpaper was an institutional mechanism that few outsiders understood. Beginning in the 1970s under CEO James Burke — the same Burke who would navigate the Tylenol crisis — J&J conducted what it called "Credo Challenge" sessions. Burke would gather groups of managers and force them to debate the Credo line by line: Did they believe it? Did it still apply? Were there situations where following it would damage the business? If managers couldn't defend the Credo, Burke said, they should take it off the wall and stop pretending.
If we aren't going to live by the Credo, let's tear it off the wall.
This was not empty theater. The Credo Challenge sessions, which ran across the company's global operations for years, served a dual function. They forced genuine engagement with the company's values at a time when most corporate mission statements were produced by PR departments and forgotten by Tuesday. And they created a shared vocabulary — a common reference framework that allowed managers in J&J's wildly decentralized structure to make decisions aligned with corporate intent without requiring centralized approval. The Credo was, in effect, a coordination mechanism disguised as a moral statement.
When the Tylenol crisis hit in 1982, Burke's response was instinctive precisely because the Credo had already been stress-tested. There was no debate about whether to pull the product. The Credo said the first responsibility was to patients and consumers. Pull the product. The Harvard Business School case study on Johnson & Johnson's culture, first published in 1983, captured this dynamic: the company's systems, structures, and procedures were designed to reflect and promote a culture in which the right decision was also the obvious one.
The Tylenol response earned J&J something that money cannot buy and advertising cannot fabricate: the benefit of the doubt. For decades afterward, when regulators questioned a product, when lawsuits were filed, when quality problems emerged, the public and the press extended Johnson & Johnson a presumption of good faith that no other pharmaceutical company enjoyed. The Credo was the shield. The Tylenol response was the proof.
The question is what happens when the shield is used to deflect accountability rather than inspire it.
The Pharma Machine Behind the Baby Powder
For most of its public life, Johnson & Johnson was perceived as a consumer products company — baby shampoo, Band-Aids, Tylenol, the comforting red script logo on products in every American medicine cabinet. This perception, while commercially useful, obscured the reality of where the money actually came from.
By the 2000s, J&J's pharmaceutical division — anchored by its subsidiary Janssen Pharmaceuticals, originally a Belgian firm acquired in 1961 — had become the engine of the enterprise. The consumer business was large, stable, and massively profitable, but it grew slowly. The medical devices business was cyclical and competitive. Pharma was where the margins lived.
The acquisition of Janssen was itself a masterclass in the J&J playbook. Paul Janssen, the Belgian physician-chemist who founded the company, had personally developed or supervised the development of more than eighty drugs over his career — an output so prolific it bordered on the implausible. J&J bought Janssen in 1961 but, crucially, let Paul Janssen keep running it. The decentralized model wasn't just organizational theory; it was how you retained a genius who might otherwise leave. Janssen Pharmaceuticals developed drugs including haloperidol (an antipsychotic), fentanyl (originally an anesthetic, later an agent of catastrophe), loperamide (Imodium), and risperidone (Risperdal). Each of these became a blockbuster. Several became controversies.
The pharmaceutical transformation accelerated through the 1990s and 2000s. J&J acquired biotech companies — Centocor in 1999 for $4.9 billion, Crucell in 2011 for $2.4 billion, Actelion in 2017 for $30 billion — building capabilities in immunology, infectious disease, and pulmonary hypertension. The crown jewel that emerged was Stelara, a monoclonal antibody for psoriasis and Crohn's disease that generated roughly $10 billion in peak annual sales, making it one of the best-selling drugs in the world.
But the pharmaceutical business also brought pharmaceutical liabilities. Risperdal, the blockbuster antipsychotic, became the subject of a Department of Justice investigation and a $2.2 billion settlement in 2013 over allegations that J&J had illegally marketed the drug for uses not approved by the FDA, including to elderly dementia patients and children. Internal documents suggested that executives had known the off-label marketing was occurring and had done little to stop it. The company denied wrongdoing as part of the settlement.
The conduct at issue in this case jeopardized the health and safety of patients and violated the public trust.
The Risperdal settlement was large but, for J&J, financially manageable — a cost of doing business in an industry where the penalties for misconduct were routinely dwarfed by the revenues the misconduct generated. It was a pattern that would repeat.
The Architecture of Decentralization
To understand how Johnson & Johnson could simultaneously be the company that pulled Tylenol from shelves at enormous cost and the company that marketed Risperdal to children, you have to understand the structure.
At its peak, J&J operated more than 250 subsidiary companies across 60 countries, selling products in over 175 nations. Each subsidiary had its own president, its own management team, its own board of directors (often including J&J corporate officers), and its own P&L. The parent company in New Brunswick set strategic direction, allocated capital, and enforced the Credo. But day-to-day operations — including, critically, marketing decisions, quality control processes, and regulatory strategy — were handled locally.
This created extraordinary advantages. The decentralized model allowed J&J to acquire companies without destroying them. It attracted entrepreneurial talent that would never tolerate a centralized bureaucracy. It enabled speed in local markets — a J&J subsidiary in Brazil could respond to Brazilian regulatory changes without waiting for New Jersey to issue guidance. And it created a portfolio effect: when one subsidiary struggled, others thrived, smoothing the conglomerate's overall performance.
The disadvantages were the mirror image. Decentralization made it harder to enforce consistent quality standards across hundreds of facilities. It created information silos where problems in one subsidiary were invisible to others. And it generated a convenient structure for deniability: when a subsidiary did something wrong, the parent company could plausibly claim it hadn't known. The same autonomy that enabled innovation also enabled misconduct to persist in the shadows of the org chart.
Between 2009 and 2011, J&J's consumer subsidiary McNeil Consumer Healthcare — the makers of Tylenol — executed a series of product recalls involving children's Tylenol, Motrin, Zyrtec, and Benadryl. The recalls were triggered by quality control failures at a manufacturing plant in Fort Washington, Pennsylvania, including reports of a musty odor caused by a chemical used to treat wooden pallets. In one particularly embarrassing episode, J&J hired contractors to quietly buy back defective Motrin from store shelves without issuing a formal recall — a maneuver later revealed by congressional investigators. The FDA issued a consent decree requiring oversight of McNeil's manufacturing operations.
For the company that had made its name through its Tylenol recall, the irony was devastating. The product that had built the brand was now the product that was eroding it.
Powder, Asbestos, and the Long Fuse
If the Risperdal settlement was financially manageable and the McNeil recalls were reputationally embarrassing, the baby powder litigation was existential — not because it threatened J&J's solvency, but because it threatened the one thing that had always been the company's ultimate asset: trust.
Johnson's Baby Powder, the talc-based product in its iconic white bottle, had been a fixture of American domestic life since the late nineteenth century. Generations of mothers dusted their infants with it. Women used it as a personal hygiene product. The powder was so closely associated with J&J's identity that it functioned less as a product and more as a symbol — of purity, of care, of the tender bond between parent and child.
The problem was that talc, the mineral from which the powder was made, is often found in geological formations alongside asbestos, a known carcinogen. Epidemiological research dating back decades had suggested links between talc use in the genital area and ovarian cancer. The danger of asbestos contamination in talc had been noted in scientific literature as early as the 1920s.
The growth and popularity of J&J baby powder grew as data about the dangers grew. They were almost alongside each other.
Investigative journalism — most notably a series of Reuters reports beginning in 2018 — revealed internal J&J documents showing that the company had known for decades about the presence of trace asbestos in some of its talc supplies. Internal memos showed that J&J executives had discussed the problem, debated how to respond, and continued selling the product. The company maintained that its products were safe and that the science supporting a link between talc and cancer was flawed.
In October 2019, the FDA detected chrysotile asbestos in a bottle of Johnson's Baby Powder purchased from an online retailer. J&J recalled 33,000 bottles. In 2020, the company discontinued talc-based baby powder sales in the United States, replacing talc with cornstarch while continuing to sell the talc formulation internationally. It attributed the U.S. discontinuation to "slumping sales fueled by misinformation."
By then, approximately 38,000 lawsuits had been filed against the company by individuals — overwhelmingly women — alleging that Johnson's Baby Powder had caused their cancer. Advocacy groups noted that J&J had specifically marketed the product to Black women. Internal marketing documents confirmed targeted campaigns.
What followed was a legal strategy that, regardless of its legality, struck many observers as a betrayal of everything the Credo purported to stand for.
The Texas Two-Step
In October 2021, J&J executed a corporate maneuver that became known as the "Texas Two-Step." The company created a new subsidiary in Texas, transferred all of its talc-related liabilities to that subsidiary, then immediately moved the subsidiary to North Carolina and had it file for bankruptcy. The strategy was designed to resolve tens of thousands of cancer lawsuits through a single bankruptcy proceeding rather than facing them one by one in courts across the country.
The logic, from J&J's perspective, was straightforward: the litigation was sprawling, expensive, and unpredictable. Jury verdicts had been enormous — a Missouri court awarded $4.69 billion to twenty-two women in 2018, later reduced but still staggering. A global settlement through bankruptcy, J&J argued, would provide certainty and fair compensation to all claimants rather than enriching a few who happened to draw sympathetic juries while others received nothing.
The logic, from the plaintiffs' perspective, was equally straightforward: a $400+ billion company was using a bankruptcy loophole to shield itself from accountability for selling a cancer-causing product to women and children for decades. The subsidiary that filed for bankruptcy, LTL Management, had essentially no assets of its own. It was a shell designed to contain liability, not to operate a business.
Federal courts ultimately rejected J&J's bankruptcy strategy — not once, but multiple times. In January 2025, a federal judge in Texas rejected J&J's proposed $9 billion settlement plan. The Third Circuit Court of Appeals and the Supreme Court had previously declined to revive earlier versions of the maneuver. J&J's legal defense, as journalist Gardiner Harris put it in his 2025 book, was "beginning to crumble."
The talc saga revealed something uncomfortable about the relationship between the Credo and the corporation. The Credo said the first responsibility was to patients and consumers. The Texas Two-Step said the first priority was managing litigation exposure. Both could not be true simultaneously.
The Kenvue Separation
Against the backdrop of the talc litigation, J&J's leadership made the most consequential structural decision in the company's 135-year history: it would separate its consumer health business entirely.
In November 2021, CEO Joaquin Duato — who had assumed the role from Alex Gorsky just months earlier — announced that J&J would spin off its consumer health division into a standalone public company. The timing was conspicuous. The consumer business, which included Band-Aid, Tylenol, Listerine, Neutrogena, Aveeno, and, yes, Johnson's Baby Powder, carried both the company's most beloved brands and its most toxic liabilities. The separation would leave "New J&J" as a focused pharmaceutical and medical technology company. The consumer business and its associated litigation exposure would belong to someone else.
Timeline of J&J's largest restructuring
Nov 2021J&J announces plan to separate its consumer health business
Jan 2023Kenvue Inc. files S-1 registration statement with the SEC
May 2023Kenvue IPO at $22/share, raising $3.8 billion — largest U.S. IPO since Rivian (2021)
Aug 2023J&J offers exchange of up to 1.53 billion Kenvue shares for J&J stock at ~7.5% premium
May 2024J&J completes debt-for-equity exchange of final 182 million Kenvue shares
2024Kenvue trades as fully independent company under KVUE on NYSE
The IPO of Kenvue Inc. on May 4, 2023, valued the consumer business at roughly $50 billion on its first day of trading, with shares jumping 22% above the $22 offering price. J&J initially retained a 90.9% stake, then systematically divested it through an exchange offer in August 2023 (offering shareholders $107.53 of Kenvue stock for every $100 of J&J stock tendered) and a final debt-for-equity exchange in May 2024. Kenvue CEO Thibaut Mongon, the former J&J consumer health chief, declared the separation a move made "from a position of strength." Kenvue had posted $14.95 billion in sales and $1.46 billion in net income for fiscal 2022.
The separation was strategically coherent: consumer health products were growing slowly, carried lower margins than pharmaceuticals, and faced intense private-label competition. Pharmaceutical and medtech businesses demanded massive R&D investment, operated under different regulatory regimes, and served entirely different customers. Bundling them together created a conglomerate discount that Wall Street increasingly penalized.
But the separation also had a less charitable reading. J&J was jettisoning the division most associated with the talc lawsuits — and with the consumer-facing trust that the Credo had been built to protect — while retaining the higher-margin pharmaceutical and device businesses. The talc liabilities remained with the J&J parent entity (and its controversial bankruptcy subsidiary), but the emotional and reputational center of the Johnson & Johnson brand — the baby products, the Band-Aids, the Tylenol — now belonged to Kenvue.
What remained was, financially, a much stronger company. But it was also a different company — one whose identity could no longer rest on the nursery-soft imagery that had defined it for over a century.
Duato and the New J&J
Joaquin Duato became J&J's eighth CEO in January 2022, and its first not born in the United States. Born in Valencia, Spain, Duato had joined J&J after initially being rejected by the company following graduate school — he didn't make it past the first round of interviews. He found his way back, spent thirty-four years rotating through geographies, sectors, and functions, and rose to run the pharmaceutical division before succeeding Alex Gorsky.
Gorsky, a West Point graduate and Army veteran who led J&J from 2012 to 2022, had steered the company through the Risperdal settlement, the McNeil consent decree, the talc escalation, and the COVID-19 vaccine development — a decade defined by simultaneous reputational erosion and financial growth. Gorsky was a polished corporate leader, comfortable on CNBC and at Davos, who projected calm competence while the legal and regulatory ground shifted beneath him. His decade produced strong financial returns and a portfolio of acquisitions (Actelion for $30 billion, Auris Health for $3.4 billion, Momenta Pharmaceuticals for $6.5 billion) that reshaped J&J's pipeline. It also produced the Texas Two-Step.
Duato inherited all of it. His stated priorities were dual: remain true to the mission of addressing difficult-to-treat diseases and maintain the principle-based, people-based culture that had always been J&J's differentiator. In one of few interviews since becoming CEO, at Fortune's CEO Initiative conference in October 2023, Duato spoke with evident pride about J&J's low attrition rate — well below industry averages — and the company's internal career mobility. "Johnson & Johnson has its internal job market," he said.
In our 130 years of history, we have had only eight CEOs. And I am the first one who is not born in the U.S. And I'm proud to represent that.
Duato's strategic agenda was clear: focus the post-Kenvue company on two growth engines. The Innovative Medicine segment (formerly Janssen) would drive pipeline development in oncology, immunology, neuroscience, and cardiovascular disease. The MedTech segment would push into surgical robotics, digital surgery, and interventional solutions. Both segments required massive R&D spending — J&J invested approximately $15.1 billion in R&D in fiscal 2024 — and both offered margins that the consumer business could never match.
The bet was that J&J could become the world's preeminent healthcare innovation company while shedding the conglomerate complexity that had defined its first 135 years. But the bet also assumed that the company's reputation — the trust capital accumulated over more than a century — would survive the separation from the consumer brands that had built it.
The Vaccine That Almost Wasn't
J&J's COVID-19 vaccine, developed by its Janssen subsidiary using an adenoviral vector platform, was authorized by the FDA for emergency use on February 27, 2021 — a genuine scientific achievement produced at extraordinary speed. It was the only single-dose COVID vaccine authorized in the United States, which made it especially valuable for hard-to-reach populations, military deployments, and developing countries where cold-chain storage for the mRNA vaccines was impractical.
It was also a commercial and reputational catastrophe. In April 2021, the FDA and CDC recommended pausing administration of the Janssen vaccine after six cases of a rare blood-clotting disorder were identified among nearly seven million doses administered. The pause lasted eleven days. But the damage to public confidence was immediate and, as it turned out, irreversible. Even after the pause was lifted, uptake cratered. The vaccine that was supposed to be J&J's contribution to ending the pandemic became instead a cautionary tale about the fragility of public trust in pharmaceutical products.
Subsequent data showed the Janssen vaccine was significantly less effective than the Pfizer and Moderna mRNA vaccines against emerging variants. The CDC eventually downgraded its recommendation, preferring mRNA vaccines. By June 2023, the Janssen vaccine's emergency use authorization was effectively withdrawn as remaining stocks expired. J&J had invested heavily in manufacturing capacity — including a partnership with Merck, brokered by the Biden administration, that was itself unprecedented — and had pledged to sell the vaccine on a not-for-profit basis during the pandemic. The financial loss was manageable. The reputational loss was not.
The vaccine episode crystallized a tension that had been building for decades. J&J's most powerful asset was public trust — the belief that Johnson & Johnson products were safe, that the company cared more about patients than profits, that the Credo meant something. But each successive controversy — Risperdal, the recalls, the talc litigation, the Texas Two-Step, the vaccine debacle — drew down that trust account without any corresponding deposits. The Tylenol response had been the ultimate deposit. Nothing since had matched it.
The Golden Era, If You Squint
Duato has called the current moment "the golden era for health innovation," and on the evidence of J&J's pipeline, he is not wrong. The company's Innovative Medicine segment posted $55.4 billion in revenue in fiscal 2024, driven by a portfolio that spans oncology (Darzalex for multiple myeloma, Carvykti for CAR-T cell therapy, Rybrevant and Lazcluze for lung cancer), immunology (Tremfya for psoriasis and ulcerative colitis, positioned as the successor to the $10 billion Stelara franchise), and neuroscience (Spravato for treatment-resistant depression, the first truly novel antidepressant mechanism in decades).
The MedTech segment, at $33.4 billion in fiscal 2024 revenue, was anchored by orthopedics (DePuy Synthes hip and knee replacements), surgery (Ethicon sutures and wound closure, the MONARCH robotic-assisted bronchoscopy platform), and cardiovascular intervention (intravascular lithotripsy from the 2023 Shockwave Medical acquisition, reportedly valued at approximately $13.1 billion). J&J was betting that robotics and digital surgery would transform the MedTech business from a commodity hardware business into a recurring-revenue platform business — the same transformation that had enriched Intuitive Surgical in general surgery.
💊
Key Pipeline Assets (2024–2025)
J&J's pharmaceutical and MedTech growth drivers
| Product | Indication | Segment | Status |
|---|
| Darzalex (daratumumab) | Multiple myeloma | Innovative Medicine | Peak/mature blockbuster |
| Tremfya (guselkumab) | Psoriasis, UC, Crohn's | Innovative Medicine | Expanding indications |
| Carvykti (ciltacabtagene) | Multiple myeloma (CAR-T) | Innovative Medicine | |
The pipeline was genuinely impressive. But it faced a challenge that every pharmaceutical company must eventually reckon with: the Stelara patent cliff. Biosimilar competition to Stelara — which had generated roughly $21.4 billion in global sales at its peak — began eroding the franchise in 2025. Analysts estimated that the loss of Stelara exclusivity could eliminate $8–10 billion in annual revenue over the next several years. The new products needed to fill an enormous hole simply to maintain the status quo.
This was the essential tension of Duato's J&J: the company was simultaneously rich with innovation and vulnerable to patent cliffs, simultaneously respected for its science and distrusted for its legal maneuvering, simultaneously a leader in healthcare and a defendant in tens of thousands of cancer lawsuits. Every element of the bull case had its mirror-image bear case. The golden era and the crisis coexisted in the same building.
The Family, the Fortune, and the Foundation
No account of Johnson & Johnson is complete without the dynasty — not the corporate dynasty of CEOs, but the actual Johnson family, whose wealth, philanthropy, and dysfunction shaped the company and the nation in ways that extended far beyond the balance sheet.
Robert Wood Johnson II, the General, did not merely run J&J. He endowed the Robert Wood Johnson Foundation, which became the largest philanthropy focused exclusively on health in the United States, with assets that would grow to exceed $11 billion. He also, through his personal fortune and the foundation's influence, reshaped American healthcare policy for decades — funding research, advocating for public health infrastructure, and incubating ideas that eventually became government programs.
The third generation was more complicated. Robert Wood Johnson III (known as "Bobby") died young. His half-brother, J. Seward Johnson Sr., became the patriarch of a family whose internal feuds and scandals would fill two books —
Undue Influence by David Margolick, which chronicled the epic court battle over J. Seward Sr.'s will, and
Crazy Rich by Jerry Oppenheimer, which excavated the power, scandal, and tragedy that attended one of America's wealthiest clans. The Johnson family's relationship to the company they founded was, by the late twentieth century, more financial than operational — they were heirs and shareholders, not managers. But the family name remained on the building, on the products, and on the Credo.
The company's own institutional history is captured in
A Company That Cares, an illustrated centennial volume that tells the authorized version of the J&J story. For a more critical examination of the broader Gilded Age context in which the company emerged, Matthew Josephson's classic
The Robber Barons remains essential reading on the era's industrial consolidation.
A Compound Fracture in the Narrative
By mid-2025, Johnson & Johnson existed in a state of productive contradiction. Financially, the company had never been stronger in pure pharmaceutical terms. The Innovative Medicine segment was delivering blockbuster growth. The MedTech segment was investing in robotics and digital platforms that could transform surgical care. The Kenvue separation had unlocked value and clarified strategic focus. Revenue for fiscal 2024 reached $88.8 billion. The company had increased its dividend for sixty-two consecutive years — a record matched by fewer than a dozen American companies.
Reputationally, the picture was darker. Gardiner Harris's 2025 book
No More Tears: The Dark Secrets of Johnson & Johnson synthesized decades of reporting into a comprehensive indictment of J&J's business practices — from baby powder and asbestos to the marketing of opioids to the COVID vaccine's troubled rollout. The courts had rejected the company's bankruptcy strategy for resolving talc claims. Juries continued to hand down large verdicts. The company that had once been synonymous with trust was now, in the public imagination, increasingly synonymous with litigation.
The paradox was structural, not personal. J&J's leaders were not uniquely cynical. They operated within a system — the American pharmaceutical and medical device industry — where the incentives for aggressive marketing, liability management, and patent extension were baked into the business model. The Credo was real. The litigation was also real. The company's defenders argued that it was possible to simultaneously believe in the Credo and defend against lawsuits that the company genuinely believed were based on flawed science. The company's critics argued that the Texas Two-Step was the Credo turned inside out — that a company whose first obligation was to patients could not in good conscience use bankruptcy law to limit the compensation available to cancer victims.
Both arguments had merit. That was what made the story so uncomfortable.
On a warm day in New Brunswick, New Jersey, in the spring of 2025, the Credo still hung in the lobby of One Johnson & Johnson Plaza, where it had hung for decades. Outside, the Raritan River flowed past the same stretch of waterfront where three brothers had opened a bandage factory 139 years earlier. Inside, a $380 billion healthcare company was building CAR-T cell therapies and surgical robots while its lawyers argued in federal court about talcum powder and bankruptcy loopholes. The Credo said the first responsibility was to patients. The 10-K said the first risk factor was litigation. Somewhere between those two documents, Johnson & Johnson continued to exist.
Johnson & Johnson's 139-year history encodes a set of operating principles that extend far beyond healthcare — principles about how to build multi-generational institutions, how to manage portfolio complexity, how trust compounds and decays, and what happens when a company's mythology collides with its incentives. What follows are the strategic lessons embedded in the J&J operating model, extracted with both admiration and skepticism.
Table of Contents
- 1.Write the constitution before the crisis.
- 2.Decentralize until it hurts — then decentralize more.
- 3.Let the acquisition keep its soul.
- 4.Own the trust premium, and never spend it cheaply.
- 5.Diversify the portfolio, not the focus.
- 6.Build the pipeline behind the blockbuster.
- 7.Shed the identity before it sheds you.
- 8.Stress-test the values, not just the strategy.
- 9.Make the dividend a discipline, not a decoration.
- 10.The Credo is not a ceiling — it is a floor.
Principle 1
Write the constitution before the crisis.
Robert Wood Johnson II wrote the Credo in 1943 — a year before J&J went public, four decades before the Tylenol crisis that would prove its worth. The timing was not accidental. Johnson understood that values articulated under pressure are suspected of being opportunistic. Values articulated in advance are treated as genuine.
When James Burke ordered the Tylenol recall in 1982, he did not need to convene a committee or commission a study. The decision was already made — it had been made forty years earlier, on a piece of paper that specified the hierarchy of obligations. The Credo didn't tell Burke what to do about cyanide-laced capsules (no document could). It told him who mattered most when the decision was ambiguous, and that was enough.
The Credo functioned as what organizational theorists call a "coordination mechanism" — a shared framework that allows decentralized actors to make aligned decisions without centralized instructions. In J&J's wildly dispersed structure, where hundreds of subsidiary presidents made thousands of daily decisions, the Credo provided a common reference point that was more reliable than any policy manual.
Benefit: Pre-committed values compress decision-making time during crises and create coherence across decentralized organizations. They also generate reputational capital that compounds over decades.
Tradeoff: A written constitution can become an excuse for not thinking critically about edge cases that the constitution's authors never imagined. It can also become a weapon of hypocrisy — a document that the company waves at the public while behaving differently in the courtroom.
Tactic for operators: Write your company's non-negotiable principles before you face the situation that will test them. Codify the hierarchy of obligations (customers, employees, community, shareholders) when you have the luxury of calm. The document should be short enough to memorize and specific enough to constrain — not a mission statement, but a decision-making framework.
Principle 2
Decentralize until it hurts — then decentralize more.
J&J's decentralized structure — 250+ subsidiaries operating with their own P&Ls, their own presidents, their own cultures — was the company's most distinctive organizational feature and its most consequential strategic choice. The General believed that healthcare markets were too diverse for centralized management. His successors maintained the structure for 80+ years.
Decentralization gave J&J an extraordinary ability to absorb acquisitions without destroying them. Paul Janssen kept running Janssen Pharmaceuticals. Ethicon kept its surgical focus. DePuy kept its orthopedic expertise. Each subsidiary operated as an entrepreneurial unit within a larger capital allocation framework. The parent company provided what a subsidiary couldn't provide for itself — capital, global distribution, regulatory expertise, the Credo — and stayed out of the rest.
🏗️
The Decentralization Premium
How J&J's structure compared to integrated pharma competitors
| Dimension | J&J (Decentralized) | Typical Large Pharma (Centralized) |
|---|
| Acquisition integration | Light-touch; preserved identity | Full integration; absorbed culture |
| Speed of local decision-making | High | Moderate to low |
| Cross-subsidiary coordination | Weak (by design) | Strong (by design) |
| Quality control consistency | Variable across units | Standardized |
| Talent retention post-acquisition | High | Often low |
Benefit: Decentralization preserves the entrepreneurial energy that made an acquisition target valuable in the first place. It also creates a natural portfolio effect — one subsidiary's downturn is offset by another's growth — and attracts talent that would flee a bureaucracy.
Tradeoff: Decentralization makes it extremely difficult to enforce consistent standards — as the McNeil recalls demonstrated. Information silos can allow problems to fester. And the structure can become a mechanism for plausible deniability: "Corporate didn't know" is both the defense and the indictment.
Tactic for operators: If you're building a multi-product or multi-market company, default to more autonomy rather than less. Centralize only what cannot be replicated locally: capital allocation, brand standards, core values, and regulatory infrastructure. Let everything else be decided by the people closest to the customer. But build audit mechanisms that catch the problems your autonomous units won't self-report.
Principle 3
Let the acquisition keep its soul.
J&J's acquisition of Janssen Pharmaceuticals in 1961 is one of the most successful pharmaceutical acquisitions in history — not because of the deal terms, but because of what J&J didn't do afterward. Paul Janssen, the founder and one of the most prolific drug developers of the twentieth century, was allowed to keep running his operation. J&J provided capital and global distribution. Janssen provided the science. The result was a pipeline that produced dozens of drugs, including several blockbusters, over the following decades.
This pattern — acquire and preserve rather than acquire and integrate — was repeated with Centocor (biologics), Crucell (vaccines), Actelion (pulmonary hypertension), and Shockwave Medical (cardiovascular intervention). J&J was not buying revenue; it was buying capabilities. And capabilities reside in people, not in assets.
Benefit: Preserving the acquired company's culture and leadership retains the talent that generated the innovation you're paying for. It also avoids the "integration tax" — the 12–24 months of organizational disruption that typically follows a large acquisition, during which the acquired business underperforms.
Tradeoff: A collection of preserved cultures can become a collection of fiefdoms. The lack of integration makes it harder to realize synergies, share best practices, or build unified technology platforms. Over time, the "let them run" philosophy can calcify into organizational fragmentation.
Tactic for operators: When you acquire a company for its talent or innovation, optimize for retention of the people who created that value. Resist the urge to immediately impose your processes, your reporting structure, your culture. The first six months after a deal closes are when you lose the people you paid to acquire. Protect them.
Principle 4
Own the trust premium, and never spend it cheaply.
J&J's most valuable asset was never a patent, a product, or a factory. It was trust — the accumulated belief, reinforced by the Tylenol response and decades of consumer familiarity, that Johnson & Johnson products were safe and that the company would do the right thing when it mattered.
Trust functions as an economic asset in healthcare in ways that have no analog in most industries. A mother choosing baby shampoo, a surgeon selecting a hip implant, a physician prescribing a biologic — all of these are decisions made under conditions of asymmetric information, where the buyer cannot independently verify the quality or safety of the product. Trust fills the information gap. And a company that has earned trust can command premium prices, gain faster regulatory approval, attract better clinical trial participants, and recover more quickly from setbacks.
J&J's Tylenol response was the defining deposit into the trust account. The Risperdal settlement, the McNeil recalls, the talc litigation, and the Texas Two-Step were withdrawals. The question is whether the account has been overdrawn.
Benefit: Trust creates a moat that competitors cannot replicate through marketing spend alone. It compresses sales cycles, enables premium pricing, and provides resilience during crises. In healthcare, where lives are at stake, trust is the ultimate competitive advantage.
Tradeoff: Trust, once lost, is nearly impossible to rebuild. And the same trust that protects a company can also insulate it from accountability — allowing problems to persist because the public assumes good faith long past the point where the evidence supports that assumption.
Tactic for operators: Treat your company's trust capital the way Berkshire Hathaway treats its cash reserves — as a scarce, irreplaceable resource that should never be spent on anything but the highest-priority use. Every decision that erodes customer trust should be evaluated not just for its immediate financial impact but for its long-term effect on the trust balance sheet.
Principle 5
Diversify the portfolio, not the focus.
For most of its history, J&J operated in three distinct industries simultaneously: pharmaceuticals, medical devices, and consumer health. This diversification smoothed earnings (consumer health was stable when pharma was volatile), reduced risk (a patent cliff in one segment didn't threaten the entire enterprise), and provided a hedge against industry-specific disruption.
But diversification also created a conglomerate discount. Wall Street analysts couldn't easily value a company that was simultaneously competing with Pfizer, Medtronic, and Procter & Gamble. The businesses had different growth profiles, different capital requirements, different margin structures. Managing all three required a corporate center that added overhead without adding value to any single business.
The Kenvue separation was J&J's acknowledgment that the diversification model had outlived its usefulness. The new J&J was focused: pharmaceuticals and medical technology, unified by their dependence on R&D, their regulatory complexity, and their high-margin economics. The decision to narrow the portfolio was itself a strategic principle — not "diversify to survive" but "focus to win."
Benefit: Portfolio diversification provides resilience and optionality. When one business struggles, others provide cash flow and stability. Diversification also creates internal talent development opportunities — executives can rotate across very different businesses.
Tradeoff: Conglomerate structures are penalized by capital markets. They create management complexity. And they can delay the recognition that a business is underperforming because the portfolio masks its weakness.
Tactic for operators: Diversify early, when you need resilience. Focus later, when you need growth. The key is timing the transition — holding a diversified portfolio too long creates a conglomerate discount, but shedding it too early removes the safety net before you need it.
Principle 6
Build the pipeline behind the blockbuster.
Every pharmaceutical company faces the same existential challenge: patents expire. Stelara, J&J's psoriasis and Crohn's disease blockbuster, generated roughly $21.4 billion in global peak sales. Biosimilar competition beginning in 2025 will erode that revenue by billions per year. The only way to survive is to build the next generation of products while the current generation is still printing money.
J&J invested approximately $15.1 billion in R&D in fiscal 2024 — roughly 17% of revenue. That spending funded more than a dozen late-stage assets across oncology, immunology, neuroscience, and cardiovascular disease. The Tremfya franchise was explicitly positioned as the Stelara successor. Carvykti represented J&J's bet on CAR-T cell therapy. Rybrevant and Lazcluze were aimed at the enormous lung cancer market.
The discipline is not merely spending money on R&D. It is spending money on R&D in the right therapeutic areas — areas where the company has existing commercial infrastructure, clinical expertise, and regulatory relationships. J&J's pipeline investments were concentrated in areas where its Janssen subsidiary already had decades of experience, maximizing the probability that new products could leverage existing capabilities.
Benefit: A continuously replenished pipeline is the only sustainable competitive advantage in pharmaceuticals. Companies that invest during the blockbuster years survive the patent cliff. Companies that milk the blockbuster and underinvest don't.
Tradeoff: Pharmaceutical R&D is extraordinarily expensive, risky, and slow. The average drug takes 10–15 years from discovery to approval. Most candidates fail. And the market rewards companies for current earnings, not for pipeline investments that won't generate revenue for years.
Tactic for operators: Don't wait for the current product cycle to peak before investing aggressively in the next one. The time to build the pipeline is when cash flows are strong enough to fund it, not when the patent cliff arrives and panic sets in. Allocate a fixed percentage of revenue to R&D and treat it as non-negotiable.
Principle 7
Shed the identity before it sheds you.
The Kenvue separation was, at its core, an act of preemptive identity surgery. J&J recognized that its future as a pharmaceutical and medtech company would be hindered by its association with consumer products — not because the consumer business was bad, but because it was different in ways that confused the market, divided management attention, and attracted litigation.
The courage of the decision lay in its acknowledgment that J&J's most recognizable assets — the baby powder, the Band-Aids, the Tylenol, the logo that every American over forty associated with childhood — were no longer the company's most
valuable assets.
Reputation is not the same as value. The consumer brands were worth roughly $50 billion. The pharmaceutical and medtech businesses were worth $330+ billion. The tail was wagging the dog.
Benefit: Shedding an identity before it constrains you allows a company to be valued for what it actually does rather than what the public thinks it does. The Kenvue separation eliminated the conglomerate discount and allowed investors to value each business on its own merits.
Tradeoff: You lose the emotional resonance of the old identity — and with it, a form of reputational capital that may be irreplaceable. "New J&J" is a pharmaceutical and medtech company that most consumers have no emotional connection to. The Credo was built for a company that served mothers and children, not just oncologists and surgeons.
Tactic for operators: If your company is known for one thing but makes its money from another, eventually the disconnect will cost you. Proactively separate the identity from the economics rather than waiting for the market to force the issue.
Principle 8
Stress-test the values, not just the strategy.
James Burke's Credo Challenge sessions — forcing managers to debate the Credo line by line, to argue whether they still believed it — represented an institutional practice that most companies never replicate. It was not enough to have values; the values had to be tested, questioned, and reaffirmed through structured confrontation.
The brilliance of the Credo Challenge was that it forced engagement without mandating agreement. Managers who couldn't defend the Credo were told to take it off the wall. This created genuine ownership: the Credo wasn't corporate imposing values from above, it was hundreds of managers choosing to recommit. The institutional muscle memory this built was precisely what enabled the Tylenol response — the decision felt instinctive because it had already been rehearsed.
Benefit: Stress-testing values creates the institutional reflexes needed for crisis response. It also identifies hypocrisy early — if managers can't defend the values, the values are probably not being lived.
Tradeoff: Stress-testing values works only if the results are taken seriously. If managers challenge the Credo and leadership ignores the challenges, the exercise becomes theater. And if the stress test reveals that the values are no longer relevant, leadership must be willing to change them or admit they've been abandoned.
Tactic for operators: Once a year, bring your leadership team together and force them to argue against your company's core values. Not as a thought exercise — as a genuine interrogation. If no one can make a convincing case against the values, either the values are truly robust or your team is afraid to speak.
Principle 9
Make the dividend a discipline, not a decoration.
J&J has increased its dividend for sixty-two consecutive years — a streak that places it among the elite "Dividend Kings" and signals a level of financial discipline that extends far beyond shareholder relations. The consecutive increase is a commitment mechanism: it forces the company to generate sufficient free cash flow every year, to manage its capital structure conservatively, and to resist the temptation to pursue value-destroying acquisitions that might compromise cash flow.
The dividend also functions as a governance tool. A company that has committed to sixty-two consecutive increases cannot easily engage in the kind of financial engineering that characterizes more aggressive pharmaceutical companies. The commitment to the dividend constrains capital allocation in ways that protect long-term shareholders at the cost of short-term flexibility.
Benefit: A long dividend streak signals financial durability, attracts a stable shareholder base, and imposes fiscal discipline on management. It creates a constituency — income-seeking investors — that acts as a check on empire-building or reckless M&A.
Tradeoff: The dividend commitment reduces financial flexibility. A company locked into dividend increases may underinvest in R&D, delay necessary restructurings, or avoid large acquisitions that would temporarily depress free cash flow. The tail can wag the dog.
Tactic for operators: Whether or not you pay a dividend, find a commitment mechanism that imposes discipline on capital allocation. The mechanism matters less than the commitment — it could be a dividend policy, a share repurchase program tied to free cash flow, or a public pledge on R&D spending. The point is to make the discipline visible and irrevocable.
Principle 10
The Credo is not a ceiling — it is a floor.
The deepest lesson of the J&J story is that having a values statement is not the same as living it. The Credo was — and remains — a remarkable document. Its hierarchy of obligations (patients first, shareholders last) was genuinely radical in 1943 and remains countercultural today. The Tylenol response proved that the Credo could drive extraordinary decisions under extreme pressure.
But the Credo was also used, consciously or unconsciously, as a shield — a way to claim moral authority that insulated the company from scrutiny. When critics raised concerns about talc safety, J&J could point to 130 years of trustworthiness. When plaintiffs sued, J&J could point to the Credo's commitment to patients. The very existence of the Credo made it harder for the public to believe that J&J might be behaving badly — which is exactly the problem.
The Credo should have been the floor of acceptable behavior — the minimum standard below which the company would not fall. Instead, it sometimes functioned as the ceiling — the maximum effort the company was willing to make toward ethical conduct, beyond which it deferred to lawyers and shareholders.
Benefit: A well-articulated values framework sets a floor that prevents the worst decisions and creates a shared vocabulary for ethical reasoning across the organization.
Tradeoff: If the floor becomes the ceiling — if the values statement becomes the substitute for genuine ethical engagement rather than its catalyst — the document does more harm than good. It enables a form of moral licensing in which past good behavior justifies present bad behavior.
Tactic for operators: Treat your values statement as the minimum expectation, not the aspiration. Ask regularly: "Are we doing the minimum the Credo requires, or are we doing what patients (customers) actually need?" The gap between those two questions is where institutional integrity lives — or dies.
Conclusion
The Trust Equation
Johnson & Johnson's 139-year history teaches a single, uncomfortable lesson: trust is the most valuable and most fragile asset any company can build. It compounds slowly, over decades and centuries, through consistent behavior and public accountability. It can be spent in an afternoon — through a bankruptcy maneuver, a concealed safety report, a marketing campaign that targets vulnerable populations.
The ten principles above are not a recipe for building the next Johnson & Johnson. They are a map of the terrain — showing where the moats are, where the quicksand is, and where the path between the two runs narrowest. The Credo is real and powerful and insufficient. Decentralization is liberating and dangerous. Trust is everything and, at the same time, not enough.
The operator's challenge is to build an institution that earns trust so deep it can survive the inevitable moment when trust is tested — and then, when that moment arrives, to choose the harder right over the easier wrong. Johnson & Johnson did that once, in September 1982, and the reputation it built lasted forty years. The question now is whether one transcendent crisis response can sustain a company through the accumulated weight of all the crises that followed.
Part IIIBusiness Breakdown
The Business at a Glance
Vital Signs
Johnson & Johnson — FY 2024
$88.8BTotal revenue
$55.4BInnovative Medicine revenue
$33.4BMedTech revenue
~$15.1BR&D investment
~$380BMarket capitalization
~94,000Employees
62 yearsConsecutive dividend increases
~67%Gross margin
Post-Kenvue, Johnson & Johnson is a two-segment healthcare company with a clear identity: develop innovative medicines and build advanced medical technology. The company operates in virtually every major healthcare market globally, sells products in over 175 countries, and maintains one of the most robust pharmaceutical pipelines in the industry. Revenue of $88.8 billion in fiscal 2024 makes it one of the largest healthcare companies in the world by revenue, behind only UnitedHealth Group (a different business model entirely) among U.S.-listed peers.
The company's financial profile is characterized by high gross margins (approximately 67%), substantial R&D intensity (~17% of revenue), and consistent free cash flow generation that supports both the dividend streak and ongoing M&A activity. J&J retains one of only two remaining AAA credit ratings among U.S. corporations (Microsoft being the other, depending on the year), though this distinction has become somewhat academic as the company navigates massive litigation reserves.
How Johnson & Johnson Makes Money
J&J's revenue comes from two segments, each with distinct economics, customers, and competitive dynamics.
💰
Revenue Breakdown — FY 2024
Two-segment structure post-Kenvue separation
| Segment | FY 2024 Revenue | % of Total | Key Products | Growth Profile |
|---|
| Innovative Medicine | ~$55.4B | ~62% | Darzalex, Stelara, Tremfya, Carvykti, Spravato, Erleada | High single-digit (ex-Stelara erosion) |
| MedTech | ~$33.4B | ~38% | DePuy Synthes, Ethicon, Biosense Webster, MONARCH, Shockwave IVL | Mid single-digit |
Innovative Medicine (~62% of revenue): This is J&J's pharmaceutical engine, operated primarily through its Janssen subsidiaries. Revenue is generated through the sale of patented branded drugs to hospitals, pharmacies, and specialty distributors, with pricing power driven by patent exclusivity and clinical differentiation. Key therapeutic areas include oncology (Darzalex generated over $10 billion in 2024 sales; Carvykti is scaling rapidly), immunology (Tremfya is the designated Stelara successor, with label expansions into ulcerative colitis and Crohn's disease), neuroscience (Spravato for treatment-resistant depression), and cardiovascular/metabolic disease. The segment's economics are characterized by high gross margins (often >80% on individual products), substantial R&D risk (late-stage failure rates of 40–50%), and vulnerability to patent expiration.
MedTech (~38% of revenue): This segment develops and sells surgical instruments, orthopedic implants, cardiovascular devices, and vision care products (Acuvue contact lenses) to hospitals, surgeons, and healthcare systems. Revenue is generated through a combination of capital equipment sales, consumable instruments, and increasingly, robotic platform placements designed to drive recurring procedure-based revenue. Key franchises include DePuy Synthes (hips, knees, spine, trauma), Ethicon (sutures, staplers, energy devices), Biosense Webster (cardiac electrophysiology catheters), and the recently integrated Shockwave Medical intravascular lithotripsy technology. MedTech margins are lower than pharma (~25–30% operating margin) but more durable — medical devices face less binary patent cliff risk than pharmaceuticals.
Competitive Position and Moat
J&J competes across two vast, distinct arenas. In pharmaceuticals, its direct competitors include Pfizer ($58.5B revenue in 2024), Roche (~$47B), AbbVie (~$56B), Merck (~$64B), and Eli Lilly (~$45B but with the highest growth rate in the industry driven by GLP-1 drugs). In MedTech, the competitors are Medtronic (~$33B), Abbott (~$42B in total but with diversified segments), Stryker (~$22B), and Boston Scientific (~$17B). No other company competes at scale in both pharma and MedTech simultaneously — a structural advantage that J&J's leadership argues enables cross-pollination of capabilities, particularly in areas like robotic surgery where pharmaceutical delivery and device engineering intersect.
Moat Sources:
-
Pipeline depth and therapeutic breadth. J&J has one of the deepest late-stage pipelines in the pharmaceutical industry, with more than a dozen potential blockbuster assets across oncology, immunology, and neuroscience. The ability to simultaneously advance assets in multiple therapeutic areas — each requiring different clinical trial designs, regulatory pathways, and commercial infrastructure — is a capability that takes decades to build and is not easily replicated.
-
Global commercial infrastructure. J&J operates in 175+ countries with established relationships with hospitals, health systems, regulators, and payers. This infrastructure lowers the cost and time required to launch new products, a significant advantage over smaller competitors who must build distribution country by country.
-
MedTech installed base. In orthopedics and surgery, J&J's DePuy Synthes and Ethicon franchises have decades of surgeon relationships and installed instrument sets. Surgeons are trained on specific systems and are reluctant to switch — creating high switching costs that function as a durable moat in device selection.
-
Balance sheet and credit quality. J&J's financial strength — one of the last remaining AAA-rated corporations — enables it to fund large acquisitions (Actelion: $30B, Shockwave: ~$13.1B) without dilutive equity issuance, providing a structural advantage in competitive M&A processes.
-
The Credo as talent retention. J&J's attrition rate is consistently below pharmaceutical industry averages. Duato has attributed this to the company's culture, internal career mobility, and sense of mission — intangible advantages that reduce recruiting costs and preserve institutional knowledge.
Moat Vulnerabilities:
-
Stelara biosimilar erosion. The single largest near-term risk to the Innovative Medicine moat is the loss of Stelara exclusivity. Biosimilar entrants could erode $8–10B in annual revenue over 2025–2028.
-
No GLP-1 franchise. Eli Lilly's tirzepatide (Mounjaro/Zepbound) and Novo Nordisk's semaglutide (Ozempic/Wegovy) represent the most significant new drug class in a generation. J&J has no competitive entry in the obesity/GLP-1 space, a gap that could widen if GLP-1s prove effective in cardiovascular disease, NASH, and other indications.
-
Litigation overhang. The unresolved talc litigation — with tens of thousands of pending claims and no accepted settlement mechanism — creates an ongoing valuation discount and management distraction.
The Flywheel
J&J's competitive flywheel operates differently in each segment but shares a common logic: invest in R&D and clinical infrastructure → develop differentiated products → commercialize globally using established infrastructure → generate cash flow → reinvest in R&D and strategic acquisitions → repeat.
How pharmaceutical and MedTech reinvestment compounds
Step 1: Massive R&D investment (~$15B/year) funds pipeline development across multiple therapeutic areas, generating a portfolio of clinical-stage assets that diversifies the risk of individual program failures.
Step 2: Regulatory approval and launch leverages J&J's global commercial infrastructure (175+ countries, established payer and hospital relationships) to achieve rapid market penetration at scale — a capability that smaller companies lack.
Step 3: Blockbuster revenue generation from successful launches produces high-margin cash flows (pharma gross margins often exceed 80%) that fund both the dividend and ongoing investment.
Step 4: Strategic acquisitions — funded by the balance sheet and cash flow — add capabilities and pipeline assets that the company cannot develop internally, or that would take too long to develop (e.g., Shockwave's intravascular lithotripsy, Actelion's pulmonary hypertension franchise).
Step 5: Acquired capabilities are preserved (not integrated into oblivion) using J&J's decentralized model, retaining the talent and innovation culture that made the target valuable.
Step 6: Reinvestment cycle continues, with each successful product generating cash that funds the next generation of R&D and M&A.
The flywheel's vulnerability is the patent cliff: when a blockbuster loses exclusivity, the cash flow that funds the entire cycle is at risk. The flywheel only works if the pipeline produces replacement products at the rate that existing products lose exclusivity — a race that J&J has won historically but that the Stelara cliff will test severely.
Growth Drivers and Strategic Outlook
J&J's growth over the next five years will be determined by five specific vectors:
1. Tremfya label expansion. Tremfya (guselkumab), an IL-23 inhibitor, is being positioned as the successor to Stelara across immunology. Recent approvals in ulcerative colitis, combined with ongoing trials in Crohn's disease and other inflammatory conditions, could make Tremfya a multi-billion-dollar franchise. Analysts estimate peak potential sales of $8–12 billion annually if all label expansions succeed. The TAM for immunology biologics globally exceeds $100 billion.
2. Oncology pipeline maturation. Darzalex continues to grow through earlier-line indications in multiple myeloma. Carvykti (CAR-T) is scaling manufacturing capacity and expanding into earlier treatment lines — the total multiple myeloma market is estimated at $30+ billion globally. Rybrevant and Lazcluze target the enormous non-small-cell lung cancer market. Collectively, J&J's oncology portfolio has the potential to exceed $25 billion in annual sales by 2028.
3. Surgical robotics (OTTAVA). J&J's OTTAVA robotic-assisted surgery platform, in development for soft-tissue surgery, represents a direct competitive challenge to Intuitive Surgical's da Vinci system, which has dominated robotic surgery with a roughly 80% market share. If OTTAVA achieves FDA clearance and commercial traction, it could transform J&J's MedTech segment from a consumables business into a platform business with recurring procedure-based revenue. The global surgical robotics market is projected to exceed $20 billion by 2030.
4. Cardiovascular intervention. The acquisition of Shockwave Medical added intravascular lithotripsy (IVL) — a technology for treating calcified coronary and peripheral artery lesions — to J&J's cardiovascular portfolio. The global interventional cardiology market exceeds $15 billion annually and is growing at high single digits. Shockwave's technology addresses a previously untreatable subset of cardiovascular disease.
5. Geographic expansion. Emerging markets, particularly in Asia-Pacific, represent significant growth opportunities for both pharmaceutical and MedTech products. China's pharmaceutical market is the second-largest globally and growing rapidly, though regulatory and geopolitical risks are substantial.
Key Risks and Debates
1. The Stelara cliff is steep and near. Stelara biosimilars began entering the market in 2025. Consensus estimates suggest $8–10 billion in revenue erosion over 2025–2028. The pipeline must fill this hole — Tremfya, Darzalex growth, and new launches must collectively replace roughly $10 billion in high-margin revenue. This is the single most important near-term execution challenge facing the company, and history shows that patent cliffs are often more severe than companies initially project.
2. Talc litigation has no resolution. Federal courts have rejected J&J's bankruptcy-based settlement strategy three times as of early 2025. The company has proposed settlements exceeding $9 billion, but plaintiffs' attorneys and judges have questioned the legality and fairness of the mechanism. If J&J is forced to litigate tens of thousands of cases individually, the financial and management cost could be staggering — not because any single verdict threatens solvency, but because the cumulative distraction and reputational damage compounds over years.
3. No GLP-1 franchise exposes a strategic gap. The GLP-1 receptor agonist class (Eli Lilly's tirzepatide, Novo Nordisk's semaglutide) is the most commercially significant pharmaceutical innovation since checkpoint inhibitors. These drugs are expanding from diabetes into obesity, cardiovascular risk reduction, NASH, sleep apnea, and potentially Alzheimer's disease. J&J has no competitive entry, which means it is absent from the fastest-growing therapeutic area in the industry. This is not an oversight — it reflects J&J's historical focus on oncology, immunology, and neuroscience — but it is a consequential strategic choice.
4. OTTAVA execution risk. J&J's surgical robotics platform has been in development for years and has not yet received FDA clearance. Intuitive Surgical's da Vinci ecosystem is deeply entrenched — surgeons are trained on it, hospitals have invested in it, and the installed base creates powerful network effects. Competing with an entrenched platform is significantly harder than competing in a nascent market. If OTTAVA underperforms or launches late, the MedTech segment's growth narrative weakens materially.
5. Pricing and regulatory risk. The
Inflation Reduction Act's Medicare drug price negotiation provisions will affect J&J's pharmaceutical portfolio. Imbruvica (a blood cancer drug) was among the first ten drugs selected for Medicare negotiation in 2023. As additional J&J products become eligible, pricing pressure could erode margins on mature franchises that currently generate the cash flow funding pipeline development.
Why Johnson & Johnson Matters
Johnson & Johnson matters not because it is the largest or most profitable healthcare company — it may be neither, depending on how you measure — but because it is the oldest continuous experiment in whether a corporation can serve multiple stakeholders simultaneously over multiple generations. The Credo was a hypothesis: that a company which puts patients before shareholders would, in the long run, produce better returns for shareholders than one which inverts that order. For decades, the hypothesis held. J&J outperformed, retained talent, built trust, and survived crises that would have destroyed lesser institutions.
The twenty-first century has complicated the experiment. The same company that pulled Tylenol from shelves used bankruptcy law to limit compensation to cancer victims. The same company that authored the Credo marketed an antipsychotic drug off-label to children. The same company that inspires lower-than-industry attrition rates faces tens of thousands of lawsuits from women who used its most iconic product. These contradictions are not evidence that the Credo is a lie. They are evidence that a values statement, no matter how eloquent or genuinely held, cannot substitute for the daily, granular, unglamorous work of living up to it.
For operators and investors, the lesson is not cynical. It is this: build the values framework early, stress-test it often, and never treat it as a completed project. The Credo's power was always in its process — in Burke's insistence on challenging it, in the institutional reflex it created, in the speed of decision-making it enabled during the 1982 crisis. When the process atrophied — when the Credo became a plaque on the wall rather than a living argument — the gap between aspiration and behavior widened. The gap is where the lawsuits live. The gap is where trust goes to die. And narrowing it, relentlessly and honestly, is the only operating discipline that matters across 139 years.
